Ginkgo Bioworks Holdings, Inc.
DNA
$7.71
-$0.14-1.78%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -37.84% | -29.50% | -21.76% | 19.74% | 8.93% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -37.84% | -29.50% | -21.76% | 19.74% | 8.93% |
| Cost of Revenue | -3.58% | -12.42% | -0.48% | 11.19% | -3.42% |
| Gross Profit | -45.03% | -33.67% | -26.77% | 21.85% | 11.93% |
| SG&A Expenses | -19.02% | -26.19% | -27.65% | -32.69% | -30.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -29.09% | -35.17% | -34.95% | -41.17% | -32.27% |
| Operating Income | 23.90% | 37.85% | 40.27% | 57.72% | 44.68% |
| Income Before Tax | 35.71% | 44.12% | 48.98% | 65.64% | 45.56% |
| Income Tax Expenses | -138.15% | -74.74% | -47.44% | -89,600.00% | -245.90% |
| Earnings from Continuing Operations | 35.86% | 44.22% | 49.03% | 65.74% | 45.61% |
| Earnings from Discontinued Operations | 14.63% | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 35.52% | 42.83% | 47.86% | 64.89% | 44.71% |
| EBIT | 23.90% | 37.85% | 40.27% | 57.72% | 44.68% |
| EBITDA | 24.82% | 40.66% | 43.15% | 60.78% | 46.65% |
| EPS Basic | 40.42% | 46.85% | 51.74% | 67.53% | 48.34% |
| Normalized Basic EPS | 27.07% | 41.39% | 43.05% | 61.59% | 48.90% |
| EPS Diluted | 40.38% | 46.86% | 51.79% | 67.55% | 48.40% |
| Normalized Diluted EPS | 27.07% | 41.37% | 43.03% | 61.58% | 48.89% |
| Average Basic Shares Outstanding | 7.31% | 6.88% | 7.57% | 7.74% | 7.63% |
| Average Diluted Shares Outstanding | 7.30% | 6.86% | 7.54% | 7.72% | 7.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |